ClinicalTrials.gov record NCT06721234

Role of Femoral Vein Wall Thickness and Inflammatory Markers in Patients With Behcet Disease

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 17, 2026

Role of Femoral Vein Wall Thickness and Inflammatory Markers in Patients With Behcet Disease

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.
Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.
Healthy volunteersAcceptedPeople who do not have the condition being studied who are allowed to take part. Some studies include both people with the condition and healthy volunteers; others may enrol only healthy volunteers.
Age19 years old to 80 years old
SexAll
LocationEgypt
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This observational study involves people with Behçet disease. It measures femoral vein wall thickness and blood inflammatory markers. The study looks for connections between those measurements, disease activity, and some clinical features.

What it is studying. Whether femoral vein wall thickness and levels of inflammatory markers are related to disease activity and certain clinical manifestations in people with Behçet.

What the researchers hope to learn. To evaluate femoral vein wall thickness and inflammatory indices in people with Behçet disease and assess their relationship to disease activity and some clinical manifestations.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

Evaluation of femoral vein wall thickness and inflammatory indices in patients with Behcet disease and assessment of their relation to the disease activity and related some clinical manifestations

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

  • Patients fulfill the International Criteria for Behcet's Disease (ICBD)
  • Age above 18 years old
  • Patients cooperative and can answer questions
  • Patients who are able and willing to give informed consent

Exclusion criteria

  • Other rheumatological and vascular diseases
  • Patients with abnormal hepatic or renal function tests , hyperlipidemia and impaired coagulation tests
  • Patients with hypertension , diabetes mellitus , malignant and active infectious diseases
  • Patients who are using aspirin and other platelet active drygs during the previous 6 months
  • patients who are not able and willing to give written consent

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

You would attend one or more study visits over about one month. During visits researchers will measure femoral vein wall thickness, assess inflammatory markers, and record clinical features related to Behçet disease. The primary outcome lists femoral vein wall thickness with a one-week timeframe. The registry record does not specify the exact methods used for these measurements or other procedures.

How the study is structured. An observational, case-control study using a cross-sectional approach. Participants have measurements taken at a single time point; the study's target duration is one month. Researchers compare measurements between groups to look for associations.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

  • The registry lists this study under Behçet. Does it apply to my diagnosis?
  • This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
  • The listed sites are in Egypt. Is any of them reachable for me, and does the study help with travel?
  • Which of the eligibility criteria would need to be checked with tests before I could join?

More on familial Mediterranean fever

This trial is also listed on this site under Behçet's disease.

Clinical trials62 trials listed for familial Mediterranean feverEvery trial the registry lists for familial Mediterranean fever, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in familial Mediterranean fever researchLatest monthly update: September 2026. Includes: Colchicine form change. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start
Dec 2, 2024 (estimated)
Primary completion
Apr 30, 2025 (estimated)
Study completion
Jul 30, 2025 (estimated)
Target enrollment
100 participants (estimated)
Last updated on registry
Dec 10, 2024
Data verified
Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor
Sohag University
Principal investigator
Engy Louis Fawzy, Principal investigator
Sohag University

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Participating sites (1)

Terms used on this page · explanations by MedicalUpdates.ai

informed consent
The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
Inclusion Criteria
The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria
The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials